fluoxetine has been researched along with clozapine in 84 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.19) | 18.7374 |
1990's | 22 (26.19) | 18.2507 |
2000's | 22 (26.19) | 29.6817 |
2010's | 37 (44.05) | 24.3611 |
2020's | 2 (2.38) | 2.80 |
Authors | Studies |
---|---|
Hamblin, MW; Monsma, FJ; Shen, Y; Sibley, DR; Ward, RP | 1 |
Dukat, M; Glennon, RA; Hufeisen, S; Lee, DK; Lee, M; McBride, A; Rangisetty, JB; Rauser, L; Roth, BL; Savage, JE | 1 |
Topliss, JG; Yoshida, F | 1 |
Keserü, GM | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Morphy, R; Rankovic, Z | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
Jia, L; Sun, H | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
Sen, S; Sinha, N | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Peters, JU | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Cassady, SL; Thaker, GK | 1 |
Brewerton, TD; Shannon, M | 1 |
Dahms, JL; Seiden, LS; Shaughnessy, RA | 1 |
Leonsegui, I; Salvador-Carulla, L | 1 |
Campbell, M; Cueva, JE | 1 |
Kingsbury, SJ; Puckett, KM | 1 |
Eales, MJ; Layeni, AO | 1 |
Goldberg, HL | 1 |
Crismon, ML; Dorson, PG; Eggert, AE | 1 |
Baldessarini, RJ; Centorrino, F; Cohen, BM; Flood, JG; Huston-Lyons, D; Volpicelli, SA | 1 |
Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Puopolo, PR; Volpicelli, SA | 1 |
Hollander, E; Hwang, MY; Simeon, D; Stein, D | 1 |
Baker, RW; Chengappa, KN; Schooler, NR; Steingard, S | 1 |
Patel, B; Tandon, R | 1 |
Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Volpicelli, SA | 1 |
Ball, P; Breier, A; Bryant, N; Buchanan, RW; Kirkpatrick, B | 1 |
Purdon, SE; Snaterse, M | 1 |
Avenoso, A; Caputi, AP; Fabrazzo, M; Facciolà, G; Maj, M; Monteleone, P; Perucca, E; Spina, E | 1 |
Ferslew, KE; Hagardorn, AN; Harlan, GC; McCormick, WF | 1 |
Aymard, N; Baldacci, C; Caroli, F; Smagghe, PO; Vacheron, MN; Viala, A | 1 |
Chang, WH; Lane, HY; Lu, ML | 1 |
Pallanti, S; Pazzagli, A; Quercioli, L; Rossi, A | 1 |
Lund, BC; Miller, DD; Perry, PJ | 1 |
Kaur, G; Kulkarni, SK | 1 |
Ferris, CF; King, JA; Messenger, T | 1 |
Rehavi, M; Roz, N; Weizman, A | 1 |
Jiang, A; LoGrasso, PV; Stearns, BA; Trauger, JW | 1 |
Conca, A; Hubmann, MR; König, P; Moll, W; Waschgler, R | 1 |
Howpage, P; Varambally, S | 1 |
Gross, G; Groth, I; Jongen-Relo, A; Rex, A; Wicke, KM | 1 |
Adachi, YU; Higuchi, H; Kazama, T; Mimuro, S; Sato, S; Satomoto, M; Watanabe, K; Yamada, S | 1 |
Fontenelle, LF; Leite, MA | 1 |
Ibi, D; Koike, H; Mizoguchi, H; Nabeshima, T; Nagai, T; Nitta, A; Takuma, K; Yamada, K; Yoneda, Y | 1 |
Crisp, KM; Grupe, RE; Lobsang, TT; Yang, X | 1 |
Barros, S; de Carvalho, J | 1 |
Akagi, T; Aruga, J; Hashikawa, T; Morimura, N; Odaka, YS; Sakoori, K; Takashima, N; Yamada, K | 1 |
Rushlow, WJ; Sutton, LP | 1 |
Andrade, C | 1 |
Bai, YY; Li, CQ; Li, F; Ruan, CS; Shen, LJ; Yang, CR; Zhang, ZG; Zheng, HY; Zhou, HF; Zhou, L; Zhou, XF | 1 |
Bernardi, RE; Bošković, M; Djordjević, S; Djurdjević, A; Filipović, D; Lazarević-Pašti, T; Todorović, N; Tomanović, N; Zlatković, J | 1 |
Bai, YY; Liu, D; Ruan, CS; Shen, LJ; Wang, XF; Yang, CR; Zheng, HY; Zhou, HF; Zhou, XF | 1 |
De Montis, MG; Ferrari, A; Gambarana, C; Pelliccia, T; Scheggi, S | 1 |
Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK | 1 |
Agrawal, T; Dhamija, E; Kar, M; Kumar, R; Medigeshi, GR | 1 |
Filipović, D; Todorović, N | 2 |
Bernardi, RE; Filipović, D; Gass, P; Inta, D; Jasnić, N; Perić, I; Stanisavljević, A | 1 |
Filipović, D; Mićić, B; Schwirtlich, M; Stevanović, M; Todorović, N | 1 |
Ahsan, MI; Jaffery, A; Jaffery, FA; Khan, RA; Masood, SM | 1 |
Du, JY; Li, F; Liang, R; Liu, Y; Meng, FJ; Ming, D; Mu, XF; Wang, S; Yang, CR; Yu, M; Zhang, FQ; Zhang, XY; Zhou, FH; Zhou, L; Zhou, XF | 1 |
Alli-Balogun, O; Bidkhanian, P; Korenis, P; Singh, G | 1 |
8 review(s) available for fluoxetine and clozapine
Article | Year |
---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Psychosocial effects in pharmacology: something more than an anecdote?].
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Clozapine; Fluoxetine; Humans; Hypnotics and Sedatives; Psychology, Social; Psychopharmacology; Triazolam | 1995 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder; Carbamazepine; Child; Child Behavior Disorders; Child, Preschool; Clonidine; Clozapine; Depressive Disorder; Dose-Response Relationship, Drug; Feeding and Eating Disorders; Fluoxetine; Humans; Imipramine; Lithium; Mutism; Obsessive-Compulsive Disorder; Phenobarbital; Phenytoin; Phobic Disorders; Schizophrenia; Sleep Wake Disorders; Tranquilizing Agents | 1995 |
Psychotropic drugs in pregnancy and lactation.
Topics: Clozapine; Embryonic and Fetal Development; Female; Fluoxetine; Humans; Lactation; Lithium; Mental Disorders; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Psychotropic Drugs; Puerperal Disorders | 1994 |
Pathological gambling and primary antiphospholipid (Hughes) syndrome: a unique neuropsychiatric association.
Topics: Antidepressive Agents; Antiphospholipid Syndrome; Antipsychotic Agents; Clomipramine; Clozapine; Fluoxetine; Fructose; Gambling; Humans; Male; Middle Aged; Topiramate | 2011 |
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2015 |
4 trial(s) available for fluoxetine and clozapine
Article | Year |
---|---|
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Psychotic Disorders; Schizophrenia; Stimulation, Chemical; Valproic Acid | 1994 |
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
Topics: Adult; Ambulatory Care; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1996 |
Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Depressive Disorder; Drug Monitoring; Female; Fluoxetine; Humans; Male; Middle Aged; Schizophrenia; Serotonin; Tryptophan | 1999 |
The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Phobic Disorders; Psychiatric Status Rating Scales; Schizophrenia, Paranoid; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
72 other study(ies) available for fluoxetine and clozapine
Article | Year |
---|---|
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Blotting, Northern; Brain Chemistry; Cell Line; Cloning, Molecular; DNA; GTP-Binding Proteins; Lysergic Acid Diethylamide; Molecular Sequence Data; Polymerase Chain Reaction; Psychotropic Drugs; Rats; Receptors, Serotonin; RNA; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 1993 |
2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
Topics: Adenylyl Cyclases; Cell Line; Enzyme Activation; Humans; Methoxydimethyltryptamines; Radioligand Assay; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Structure-Activity Relationship; Tryptamines | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Addition of fluoxetine to clozapine.
Topics: Adult; Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Male; Schizophrenia; Schizophrenic Psychology | 1992 |
Possible clozapine exacerbation of bulimia nervosa.
Topics: Acute Disease; Adult; Bulimia; Clozapine; Dyskinesia, Drug-Induced; Female; Fluoxetine; Humans; Recurrence; Schizophrenia; Thiothixene | 1992 |
Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule.
Topics: Animals; Antidepressive Agents; Bupropion; Clozapine; Drug Evaluation, Preclinical; Electroshock; Fluoxetine; Haloperidol; Male; Propiophenones; Rats; Rats, Inbred Strains; Reinforcement Schedule; Trazodone; Zimeldine | 1985 |
Effects of fluoxetine on serum clozapine levels.
Topics: Adult; Clonazepam; Clozapine; Drug Interactions; Drug Therapy, Combination; Epilepsies, Myoclonic; Fluoxetine; Humans; Lorazepam; Male; Schizophrenia, Paranoid | 1995 |
Exacerbation of obsessive-compulsive symptoms associated with clozapine.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia; Schizophrenic Psychology | 1994 |
Lack of effect of fluoxetine on plasma clozapine concentrations.
Topics: Adult; Clozapine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Male; Schizophrenia; Stimulation, Chemical | 1994 |
Tissue concentrations of clozapine and its metabolites in the rat.
Topics: Animals; Brain; Clozapine; Fluoxetine; Half-Life; Male; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Valproic Acid | 1993 |
Clozapine, obsessive symptoms, and serotonergic mechanisms.
Topics: Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia; Schizophrenic Psychology | 1993 |
Clozapine, obsessive symptoms, and serotonergic mechanisms.
Topics: Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Receptors, Serotonin | 1993 |
Development of obsessive-compulsive symptoms during clozapine treatment.
Topics: Adult; Clozapine; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia | 1993 |
Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Affective Disorders, Psychotic; Aged; Ambulatory Care; Clozapine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Middle Aged; Paroxetine; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Stimulation, Chemical | 1996 |
Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia.
Topics: 1-Naphthylamine; Adult; Antipsychotic Agents; Clozapine; Cognition; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Humans; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Biotransformation; Chronic Disease; Clozapine; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Schizophrenia | 1998 |
A fatal drug interaction between clozapine and fluoxetine.
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Drug Overdose; Fatal Outcome; Fluoxetine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 1998 |
Selective serotonin reuptake inhibitor syndrome: precipitated by concomitant clozapine?
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Substance Withdrawal Syndrome | 1999 |
Treating depression in schizophrenia.
Topics: Antidepressive Agents; Antipsychotic Agents; Clozapine; Comorbidity; Depressive Disorder; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoxetine; Humans; Schizophrenia; Schizophrenic Psychology; Secondary Prevention | 2001 |
Studies on modulation of feeding behavior by atypical antipsychotics in female mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adipose Tissue; Animals; Antipsychotic Agents; Body Weight; Clozapine; Eating; Feeding Behavior; Female; Fluoxetine; Hyperphagia; Mice; Mice, Inbred Strains; Organ Size; Quinpirole; Quipazine; Selective Serotonin Reuptake Inhibitors; Weight Gain | 2002 |
Seed finding in golden hamsters: a potential animal model for screening anxiolytic drugs.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety; Appetitive Behavior; Behavior, Animal; Buspirone; Chlordiazepoxide; Clozapine; Cricetinae; Desipramine; Drug Evaluation, Preclinical; Fasting; Fluoxetine; Injections, Intraperitoneal; Male; Mesocricetus; Models, Animal; Stress, Psychological; Yohimbine | 2002 |
Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
Topics: Animals; Antipsychotic Agents; Binding Sites; Biological Transport; Brain; Brain Chemistry; Clozapine; Drug Administration Schedule; Fluoxetine; Haloperidol; In Situ Hybridization; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Paroxetine; Piperazines; Rats; Tetrabenazine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2002 |
Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2).
Topics: 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific); 3-Hydroxysteroid Dehydrogenases; 5-alpha-Dihydroprogesterone; Carbamazepine; Catalysis; Clozapine; Enzyme Activation; Enzyme Inhibitors; Fluoxetine; Flurbiprofen; Humans; Hydroxysteroid Dehydrogenases; Kinetics; Oxidation-Reduction; Pregnanediones; Pregnanolone; Recombinant Fusion Proteins; Selective Serotonin Reuptake Inhibitors; Substrate Specificity; Ursodeoxycholic Acid | 2002 |
Simultaneous quantification of citalopram, clozapine, fluoxetine, norfluoxetine, maprotiline, desmethylmaprotiline and trazodone in human serum by HPLC analysis.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chromatography, High Pressure Liquid; Citalopram; Clozapine; Fluoxetine; Humans; Maprotiline; Trazodone | 2002 |
Acute myocarditis associated with clozapine.
Topics: Acute Disease; Adult; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Lithium Compounds; Male; Myocarditis; Psychotic Disorders; Risk Factors | 2007 |
The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Clozapine; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Investigational; Fluoxetine; Guinea Pigs; Injections, Intraperitoneal; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Selective Serotonin Reuptake Inhibitors; Swimming; Tranylcypromine | 2007 |
Isoflurane anesthesia inhibits clozapine- and risperidone-induced dopamine release and anesthesia-induced changes in dopamine metabolism was modified by fluoxetine in the rat striatum: an in vivo microdialysis study.
Topics: Anesthetics, Inhalation; Animals; Chromatography, High Pressure Liquid; Clozapine; Corpus Striatum; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Fluid; Fluoxetine; Isoflurane; Male; Microdialysis; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Synaptic Transmission | 2008 |
Treatment-resistant self-mutilation, tics, and obsessive-compulsive disorder in neuroacanthocytosis: a mouth guard as a therapeutic approach.
Topics: Adult; Antipsychotic Agents; Atrophy; Caudate Nucleus; Clonazepam; Clozapine; Dibenzothiazepines; Electromyography; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Mouth Protectors; Neuroacanthocytosis; Obsessive-Compulsive Disorder; Quetiapine Fumarate; Self-Injurious Behavior | 2008 |
Behavioral abnormality and pharmacologic response in social isolation-reared mice.
Topics: Aggression; Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Clozapine; Cognition; Emotions; Fluoxetine; Male; Methylphenidate; Mice; Mice, Inbred ICR; Social Behavior; Social Isolation; Stress, Psychological | 2009 |
Biogenic amines modulate pulse rate in the dorsal blood vessel of Lumbriculus variegatus.
Topics: 5-Methoxytryptamine; Animals; Antidepressive Agents, Tricyclic; Biogenic Amines; Blood Vessels; Clozapine; Cyproheptadine; Drug Antagonism; Fluoxetine; Heart Rate; Imines; Octopamine; Oligochaeta; Reserpine; Serotonin; Theophylline | 2010 |
Impaired cognitive function and altered hippocampal synapse morphology in mice lacking Lrrtm1, a gene associated with schizophrenia.
Topics: Adaptation, Psychological; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition; Dizocilpine Maleate; Environment; Fluoxetine; Gene Targeting; Genetic Predisposition to Disease; Hippocampus; Membrane Proteins; Memory; Mice; Mice, Knockout; Nerve Tissue Proteins; Neural Cell Adhesion Molecules; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Synapses | 2011 |
The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; beta Catenin; Blotting, Western; Brain; Clozapine; Fluoxetine; Glycogen Synthase Kinase 3; Haloperidol; Imipramine; Immunoprecipitation; Lithium; Male; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; Valproic Acid | 2011 |
Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Topics: Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Clomipramine; Clozapine; Comorbidity; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2012 |
Foraging activity is reduced in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Appetitive Behavior; Body Weight; Cerebral Cortex; Chronic Disease; Clozapine; Depressive Disorder; Disease Models, Animal; Exploratory Behavior; Feeding Behavior; Fluoxetine; Freezing Reaction, Cataleptic; Glial Fibrillary Acidic Protein; Hippocampus; Male; Mice; Mice, Inbred C57BL; RNA, Messenger; Stress, Psychological | 2014 |
Chronic administration of fluoxetine or clozapine induces oxidative stress in rat liver: a histopathological study.
Topics: Alanine Transaminase; Animals; Antidepressive Agents; Antipsychotic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Clozapine; Cyclooxygenase 2; Fluoxetine; Glutathione; Glutathione Transferase; Liver; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Oxidative Stress; Rats, Wistar; Superoxide Dismutase | 2014 |
Enhanced aggressive behaviour in a mouse model of depression.
Topics: Aggression; Animals; Antidepressive Agents, Second-Generation; Clozapine; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Male; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; RNA, Messenger; Social Dominance; Stress, Psychological | 2015 |
Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Dietary Sucrose; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Eating; Fluoxetine; Haloperidol; Imipramine; Lithium Compounds; Male; Motivation; Nucleus Accumbens; Phosphorylation; Rats, Sprague-Dawley; Stress, Psychological | 2015 |
N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle.
Topics: A549 Cells; Animals; Antipsychotic Agents; Antiviral Agents; Bronchodilator Agents; Cell Line; Cell Line, Tumor; Clozapine; Cricetinae; Dengue Virus; Drug Repositioning; Epithelial Cells; Fluoxetine; Hepatocytes; Humans; Inhibitory Concentration 50; RNA, Viral; Salmeterol Xinafoate; Virus Replication | 2016 |
Prefrontal cortical glutathione-dependent defense and proinflammatory mediators in chronically isolated rats: Modulation by fluoxetine or clozapine.
Topics: Animals; Antidepressive Agents; Clozapine; Cytokines; Defense Mechanisms; Disease Models, Animal; Fluoxetine; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Male; Mood Disorders; NADP; NF-kappa B; Nitric Oxide Synthase Type II; Prefrontal Cortex; Rats; Rats, Wistar; Social Isolation | 2017 |
The antidepressant- and anxiolytic-like effects of fluoxetine and clozapine in chronically isolated rats involve inhibition of hippocampal TNF-α.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Clozapine; Fluoxetine; Hippocampus; Male; NF-kappa B; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2017 |
Chronic Treatment with Fluoxetine or Clozapine of Socially Isolated Rats Prevents Subsector-Specific Reduction of Parvalbumin Immunoreactive Cells in the Hippocampus.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cell Count; Clozapine; Fluoxetine; Hippocampus; Interneurons; Male; Parvalbumins; Random Allocation; Rats, Wistar; Social Isolation; Stress, Psychological | 2018 |
Subregion-specific Protective Effects of Fluoxetine and Clozapine on Parvalbumin Expression in Medial Prefrontal Cortex of Chronically Isolated Rats.
Topics: Animals; Caspase 3; Cell Count; Clozapine; Depression; Fluoxetine; Male; Neurons; Neuroprotective Agents; Parvalbumins; Prefrontal Cortex; Rats; Social Isolation | 2019 |
In vivo study to compare the effects of Choline with Fluoxetine and Clozapine for the modulation of cognitive behavior (Learning Memory and Exploratory Behavior).
Topics: Animals; Antipsychotic Agents; Choline; Clozapine; Cognition; Exploratory Behavior; Fluoxetine; Learning; Male; Maze Learning; Memory; Motor Activity; Rats | 2019 |
Antidepressant Drugs Correct the Imbalance Between proBDNF/p75NTR/Sortilin and Mature BDNF/TrkB in the Brain of Mice with Chronic Stress.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Clozapine; Fluoxetine; Hippocampus; Male; Membrane Glycoproteins; Mice; Protein Precursors; Protein-Tyrosine Kinases; Receptors, Nerve Growth Factor; Signal Transduction; Stress, Psychological | 2020 |
Clozapine Toxicity From Drug-Drug Interaction When Given With Fluoxetine and Diltiazem.
Topics: Antipsychotic Agents; Clozapine; Diltiazem; Drug Interactions; Fluoxetine; Humans | 2023 |